These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 23561712)

  • 1. Prospective randomized placebo-controlled study to assess the safety and efficacy of silodosin in the management of acute urinary retention.
    Kumar S; Tiwari DP; Ganesamoni R; Singh SK
    Urology; 2013 Jul; 82(1):171-5. PubMed ID: 23561712
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Safety of Silodosin and Dutasteride Combination Therapy in Acute Urinary Retention due to Benign Prostatic Hyperplasia: A Single-Arm Prospective Study.
    Hagiwara K; Koie T; Iwamura H; Imai A; Hatakeyama S; Yoneyama T; Hashimoto Y; Ohyama C
    Biomed Res Int; 2016; 2016():4975851. PubMed ID: 27195288
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of acute urinary retention: a worldwide survey of 6074 men with benign prostatic hyperplasia.
    Fitzpatrick JM; Desgrandchamps F; Adjali K; Gomez Guerra L; Hong SJ; El Khalid S; Ratana-Olarn K;
    BJU Int; 2012 Jan; 109(1):88-95. PubMed ID: 22117624
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alfuzosin 10 mg once daily increases the chances of successful trial without catheter after acute urinary retention secondary to benign prostate hyperplasia.
    Tiong HY; Tibung MJ; Macalalag M; Li MK; Consigliere D
    Urol Int; 2009; 83(1):44-8. PubMed ID: 19641358
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Individual patient data from registrational trials of silodosin in the treatment of non-neurogenic male lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH): subgroup analyses of efficacy and safety data.
    Novara G; Chapple CR; Montorsi F
    BJU Int; 2015 May; 115(5):802-14. PubMed ID: 25130493
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Factors predicting the success of a trial without catheter in acute urinary retention secondary to benign prostatic hyperplasia.
    Bhomi KK; Bhattachan CL
    Nepal Med Coll J; 2011 Sep; 13(3):178-81. PubMed ID: 22808810
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The management of acute urinary retention in France: a cross-sectional survey in 2618 men with benign prostatic hyperplasia.
    Desgrandchamps F; De La Taille A; Doublet JD;
    BJU Int; 2006 Apr; 97(4):727-33. PubMed ID: 16536763
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Does the duration of catheterization have an impact on the outcome of trial without catheter in patients with acute urine retention (AUR) due to benign prostatic hyperplasia (BPH)? A prospective randomized study.
    Abuelnaga M; Elawady H; Mahmoud MA; Mostafa D; Samir M
    Urologia; 2024 Feb; 91(1):107-111. PubMed ID: 38044812
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alfuzosin 10 mg once daily in the management of acute urinary retention: results of a double-blind placebo-controlled study.
    McNeill SA; Hargreave TB; Roehrborn CG;
    Urology; 2005 Jan; 65(1):83-9; discussion 89-90. PubMed ID: 15667868
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized controlled trial on the efficacy of bladder training before removing the indwelling urinary catheter in patients with acute urinary retention associated with benign prostatic hyperplasia.
    Zhengyong Y; Changxiao H; Shibing Y; Caiwen W
    Scand J Urol; 2014 Aug; 48(4):400-4. PubMed ID: 24697345
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Silodosin, a new alpha1A-adrenoceptor-selective antagonist for treating benign prostatic hyperplasia: results of a phase III randomized, placebo-controlled, double-blind study in Japanese men.
    Kawabe K; Yoshida M; Homma Y;
    BJU Int; 2006 Nov; 98(5):1019-24. PubMed ID: 16945121
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of combined use of ketoconazole and tamsulosin in management of acute urinary retention due to benign prostatic obstruction (a randomized controlled trial).
    Elbendary M; El-Gamal OM; Soliman MG; Tawfik A; Taha MR
    Prostate Cancer Prostatic Dis; 2013 Dec; 16(4):362-6. PubMed ID: 24018711
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Six-year follow up of silodosin monotherapy for the treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: What are the factors for continuation or withdrawal?
    Yamanishi T; Kaga K; Fuse M; Shibata C; Kamai T; Uchiyama T
    Int J Urol; 2015 Dec; 22(12):1143-8. PubMed ID: 26310102
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Experience of the use of silodosin in acute urinary retention caused by benign prostatic hyperplasia].
    Neĭmark AI; Nozdrachev NA
    Urologiia; 2013; (4):47-8, 50-1. PubMed ID: 24159765
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of silodosin in comparison to tamsulosin in benign prostatic hyperplasia: a randomized controlled trial.
    Pande S; Hazra A; Kundu AK
    Indian J Pharmacol; 2014; 46(6):601-7. PubMed ID: 25538330
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictors of successful trial without catheter following acute urinary retention in benign prostatic enlargement: A single centre, multivariate analysis.
    Bansal A; Arora A
    Neurourol Urodyn; 2017 Sep; 36(7):1757-1762. PubMed ID: 28101889
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A pooled analysis of individual patient data from registrational trials of silodosin in the treatment of non-neurogenic male lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH).
    Novara G; Chapple CR; Montorsi F
    BJU Int; 2014 Sep; 114(3):427-33. PubMed ID: 24571313
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Silodosin therapy for lower urinary tract symptoms in men with suspected benign prostatic hyperplasia: results of an international, randomized, double-blind, placebo- and active-controlled clinical trial performed in Europe.
    Chapple CR; Montorsi F; Tammela TL; Wirth M; Koldewijn E; Fernández Fernández E;
    Eur Urol; 2011 Mar; 59(3):342-52. PubMed ID: 21109344
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Non-inferiority of silodosin to tamsulosin in treating patients with lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH).
    Yu HJ; Lin AT; Yang SS; Tsui KH; Wu HC; Cheng CL; Cheng HL; Wu TT; Chiang PH
    BJU Int; 2011 Dec; 108(11):1843-8. PubMed ID: 21592295
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prostate size influences the outcome after presenting with acute urinary retention.
    McNeill AS; Rizvi S; Byrne DJ
    BJU Int; 2004 Sep; 94(4):559-62. PubMed ID: 15329112
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.